Cyclacel Pharmaceuticals Inc (CYCC)’s stock has witnessed a price declined of -28.58% from the previous close with its current price standing at $0.24. Its current price is -99.40% under its 52-week high of $39.84 and -3.92% more than its 52-week low of $0.25. Based on the past 30-day period, the stock price is -86.13% below the high and +4.35% above the low.
The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, CYCC’s SMA-200 is $6.3131.
Additionally, it is important to take into account CYCC stock ratios, including its price-to-sales ratio, which is 570.68 for the last tewlve months.CYCC’s price to book ratio for the most recent quarter was 1.02, resulting in an 1.65 price to cash per share for the period.
How does Cyclacel Pharmaceuticals Inc (CYCC) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 0 brokerage firms that recommend the stock as a Strong Sell. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 0.00 in simple terms.
Cyclacel Pharmaceuticals Inc (CYCC): Earnings History
If we examine Cyclacel Pharmaceuticals Inc’s recent earnings history, in the last quarter ended on 9/30/2024, it posted adjusted earnings per share of -$2.88, slashing the consensus of -$8.64. In other words, it beat the consensus by $5.76, resulting in a 66.67% surprise. In the 3 months period before the previous quarter which was closed on 9/30/2024, the stock recorded adjusted earnings per share of -$2.88 in contrast with the Outlook of -$8.64. That was a difference of $5.76 and a surprise of 66.67%.
Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) Ownership Details
I will give a breakdown of the key shareholders in Cyclacel Pharmaceuticals Inc (CYCC). Recent figures show that the company’s insiders hold 61.49% of shares. A total of 22 institutional investors hold shares in the company, making 6.64% of its stock and 17.24% of its float.
Mar 31, 2025 , it was reported that the Company’s largest institutional holder is Armistice Capital, LLC holding total of 79.34 shares that make 0.33% of the company’s total number of shares and are currently priced at 19272.0.
The securities firm Shay Capital LLC holds 6.93 shares of CYCC, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 0.03% , and the holding percentage of shares is valued at 1683.0.
An overview of Cyclacel Pharmaceuticals Inc’s technicals
In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Cyclacel Pharmaceuticals Inc (CYCC) traded 4,066,708 shares per day, with a moving average of $0.4068 and price change of -1.4300. With the moving average of $2.0085 and a price change of -3.1376, about 1,871,557 shares changed hands on average over the past 50 days. Finally, CYCC’s 100-day average volume is 943,875 shares, alongside a moving average of $3.3530 and a price change of -5.0304.
